## FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
--	--

1. Name and Address of Reporting Person\*

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

2. Issuer Name **and** Ticker or Trading Symbol

OMB APPROVAL								
OMB Number:	3235-0287							

L		
	hours per response:	0.5
	Estimated average burden	

5. Relationship of Reporting Person(s) to Issuer

					ACURA PHARMACEUTICALS, INC [ ACUR ]								Dire			X 10% C	Dwner			
(Last) (First) (Middle)															Offic belo	er (give title w)		Other below	(specify )	
47 HULF	ISH STRE	ET					of Ea 201		t Trans	action (I	Nonth	/Day/Year)								
SUITE 3	10					fΔm	endr	ment	Date		al Filo	d (Month/D		<u> </u>	6	Individual	or loipt/Grou	in Eil	ing (Check A	Annlicable
(Street)					- 4.1	If Amendment, Date of Original Filed (Month/Day/Year)									ne)			eporting Pers		
PRINCE	TON NJ	(	8542														n filed by M		nan One Rep	
(City)	(St	ate) (.	Zip)													rei	5011			
		Tabl	e I - No	on-Deriv	vative	e Se	ecu	ritie	s Ac	quired	, Dis	sposed o	f, or	Bene	eficia	ally Own	ed			
1. Title of S	Security (Inst	r. 3)		2. Transa Date (Month/D		Execution Date, (ear) if any		3. Transa Code ( 8)		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 5)			3, 4 and Secur Bene		cially I Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
										Code	v	Amount	(A) (D)	or	Price	Transa	ction(s) 3 and 4)			(
Common	Stock			04/02/	2013	2013				S		7,416(1)	D \$2.		\$2.15	<sup>5(2)</sup> 9,578,749		I		See footnote <sup>(3)</sup>
		Та	ble II -	Derivat	tive S	Secu	uriti s. w	ies /	Acqu ants.	ired, E	Dispo	osed of, onvertib	or Be	nefi	cially ies)	y Owned			<u> </u>	
1. Title of Derivative	2. Conversion	3. Transaction Date	3A. Deer Executio	med	4. Transa		!	5. Nui of		6. Date	Exerci	isable and	7. Titl	e and		8. Price of Derivative	9. Number derivative	of	10. Ownership	11. Nature of Indirect
Security (Instr. 3)	or Exercise Price of	(Month/Day/Year)	if any	Day/Year)	Code 8)		r.   !	Deriva Secui	rities	Underlying					Security Securities (Instr. 5) Beneficial			Form: Direct (D)	Beneficial Ownership	
	Derivative Security						- 10	Acqui (A) or Dispo	·				Deriva Secur and 4	ity (In:	str. 3		Owned Following Reported		or Indirect (I) (Instr. 4)	(Instr. 4)
								of (D) (Instr.	3, 4							Transaction (Instr. 4)				
						Γ		and 5	,						ount					
										Date		Expiration		or Nun of	nber					
					Code	v	1	(A)	(D)	Exercis	able	Date	Title	Sha	res					
	d Address of CAPITA	Reporting Person <sup>*</sup> L II LLC																		
(Last)		(First)	(Mic	ddle)																
47 HULFISH STREET																				
SUITE 3	10																			
(Street)																				
PRINCE	ΓΟΝ	NJ	085	542																
(City)		(State)	(Zip	))																
1. Name and Address of Reporting Person <sup>*</sup> CARE CAPITAL INVESTMENTS II LP																				
(Last)		(First)	(Mio	ddle)																
47 HULFISH STREET																				
SUITE 3	10																			
(Street) PRINCE	TON	NJ	085	542																
(City)		(State)	(Zip	)																
		Reporting Person <sup>*</sup> shore Investn	<u>ients I</u>	<u>I LP</u>																

(Last) (First) (Middle)

## 47 HULFISH STREET SUITE 310

(Street) PRINCETON	NJ	08542			
(City)	(State)	(Zip)			

## Explanation of Responses:

1. The shares were sold as follows: 6,930 by Care Capital Investments II, LP and 486 by Care Capital Offshore Investments II, L.P.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$2.15 to \$2.20, inclusive. The reporting person undertakes to provide to Acura Pharmaceuticals, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

3. Consists of 8,963,812 shares held by Care Capital Investments II, LP and 614,937 shares held by Care Capital Offshore Investments II, L.P. Care Capital II, LLC is the general partner of Care Capital Investments II, LP and Care Capital Offshore Investments II, LP and as a result, Care Capital II, LLC has the ultimate power to vote or direct the vote and to dispose or direct the disposition of such shares. Care Capital II, LLC is managed by three or more members and accordingly none of the managing members is deemed to have voting or dispositive control over the securities.

<u>Care Capital LLC /s/ David R.</u> <u>Ramsay</u>	<u>04/04/2013</u>
<u>Care Capital Investments II,</u> <u>LP, By: Care Capital II, LLC,</u> <u>Its General Partner /s/ David R.</u> <u>Ramsay</u>	<u>04/04/2013</u>
<u>Care Capital Offshore</u> <u>Investments II, LP, By: Care</u> <u>Capital II, LLC, Its General</u> <u>Partner /s/ David R. Ramsay</u>	<u>04/04/2013</u>
** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.